[European drug policy].
The European harmonization of pharmaceutical legislation was completed in 1992, but the harmonization of marketing authorizations still requires the creation of an "European medicines evaluation agency", From january 1995, two complementary marketing authorization procedures will have to be established for human and veterinary medicines in the European Community: a decentralised procedure for most products, and a centralised procedure, only valid for innovative products. At the same time, a better coordination of the assessment of adverse drug reactions (pharmacovigilance) should be achieved.